CG Oncology, Inc. Revenue from Contract with Customer, Including Assessed Tax
CG Oncology, Inc. (CGON) reported Revenue from Contract with Customer, Including Assessed Tax of $1.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-06
- CG Oncology, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $1.16M.
- CG Oncology, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $1.08M, a 1982.69% increase year-over-year.
- CG Oncology, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $2.32M, a 409.21% increase year-over-year.
- CG Oncology, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $1.67M, a 3774.42% increase year-over-year.
- CG Oncology, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $4.04M, a 254.70% increase from fiscal 2024.
- CG Oncology, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $1.14M, a 458.33% increase from fiscal 2023.
- CG Oncology, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $204.00K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.16M 10-Q · filed 2026-08-06 | $2.24M 10-Q · filed 2026-08-06 | $4.56M derived: sum of 3 quarters · filed 2026-08-06 | $6.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.08M 10-Q · filed 2026-05-08 | $3.40M derived: sum of 2 quarters · filed 2026-05-08 | $5.07M derived: sum of 3 quarters · filed 2026-05-08 | $5.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.99M derived: sum of 2 quarters · filed 2026-02-27 | $3.99M derived: sum of 3 quarters · filed 2026-08-06 | $4.04M 10-K · filed 2026-02-27 |
| 2025-09-30 | $1.67M 10-Q · filed 2025-11-14 | $1.67M derived: sum of 2 quarters · filed 2026-08-06 | $1.72M 10-Q · filed 2025-11-14 | $2.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $52.00K 10-Q · filed 2026-08-06 | $508.00K derived: sum of 3 quarters · filed 2026-08-06 | $551.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $52.00K 10-Q · filed 2026-05-08 | $508.00K derived: sum of 2 quarters · filed 2026-05-08 | $551.00K derived: sum of 3 quarters · filed 2026-05-08 | $662.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $499.00K derived: sum of 2 quarters · filed 2026-02-27 | $610.00K derived: sum of 3 quarters · filed 2026-02-27 | $1.14M 10-K · filed 2026-02-27 |
| 2024-09-30 | $43.00K 10-Q · filed 2025-11-14 | $154.00K derived: sum of 2 quarters · filed 2025-11-14 | $683.00K 10-Q · filed 2025-11-14 | $684.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $111.00K 10-Q · filed 2025-08-08 | $640.00K 10-Q · filed 2025-08-08 | $641.00K derived: sum of 3 quarters · filed 2026-02-27 | $650.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $529.00K 10-Q · filed 2025-05-13 | $530.00K derived: sum of 2 quarters · filed 2026-02-27 | $539.00K derived: sum of 3 quarters · filed 2026-02-27 | $539.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $10.00K derived: sum of 2 quarters · filed 2026-02-27 | $10.00K derived: sum of 3 quarters · filed 2026-02-27 | $204.00K 10-K · filed 2026-02-27 |
| 2023-09-30 | $9.00K 10-Q · filed 2024-11-12 | $9.00K derived: sum of 2 quarters · filed 2024-11-12 | $203.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $194.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $194.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |